In December 2024, the FDA approved Zepbound (tirzepatide) as the first prescription medication for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — a genuine milestone, because until then the only treatments were devices like CPAP, oral appliances, or surgery.
But there's a lot of confusing information circulating about it — especially around what "tirzepatide for sleep apnea" does and doesn't mean. This page lays out the honest version.
What the FDA actually approved
The specifics
- What: Zepbound (brand-name tirzepatide, made by Eli Lilly)
- For: Moderate-to-severe obstructive sleep apnea in adults with obesity
- Alongside: A reduced-calorie diet and increased physical activity
- When: December 2024 — the first medication ever approved for OSA
- Based on: Two 52-week clinical trials (SURMOUNT-OSA) totaling 469 adults, where Zepbound significantly reduced apnea and hypopnea events compared to placebo
How it works — and this part matters
Zepbound does not act on the brain's sleep centers or change your sleep architecture directly. Its benefit for sleep apnea comes almost entirely through weight loss.
Here's the mechanism: tirzepatide reduces appetite and body weight, which reduces fat deposits around the upper airway. Less fat crowding the airway means it's less likely to collapse during sleep — which is what drives the improvement in OSA severity. In other words, Zepbound treats sleep apnea by treating the obesity that contributes to it.
That's why the approval is specifically for people who have moderate-to-severe OSA and obesity — the medication works through the weight-loss pathway, so it's tied to that population.
"Zepbound" and "compounded tirzepatide" are not the same thing — and only one of them is FDA-approved for sleep apnea.
Brand-name Zepbound
✓ FDA-approved for OSAEli Lilly's product, backed by the SURMOUNT-OSA trials. This is the one with the sleep apnea indication.
Compounded tirzepatide
✗ Not FDA-approved for OSASame active molecule, but compounded products are not FDA-approved for any indication, including sleep apnea. Often used off-label for weight management under a provider's care.
So if the sleep apnea indication specifically is what you're after, brand-name Zepbound — prescribed by a licensed provider — is the FDA-approved option.
Who the approval applies to
Zepbound for OSA is intended for adults who have both:
- Moderate-to-severe obstructive sleep apnea (typically confirmed by a sleep study), and
- Obesity
It's not a standalone "sleep pill," it's not approved for mild OSA, and it's not a replacement for CPAP that you'd start on your own. If you use CPAP or another PAP device, don't stop it on your own — that's a decision for your sleep physician, ideally based on a follow-up sleep study.
Providers offering provider-led Zepbound care
If you and your clinician are considering Zepbound, SHED offers provider-led evaluations and, where clinically appropriate and prescribed, access to brand-name Zepbound (tirzepatide) delivered to your door. A licensed provider decides whether it's right for you.
Affiliate links — we may earn a commission at no cost to you. These are provider platforms; access to any specific medication, including Zepbound, is determined by a licensed clinician and your eligibility, not guaranteed.
The insurance angle worth knowing
Because Zepbound now carries a specific OSA indication, some people who couldn't get a GLP-1 covered for weight loss alone may have a coverage path for sleep apnea. Coverage still typically requires prior authorization and documentation (often including a sleep study), and it varies widely by plan — but the OSA indication is the foundation of many successful coverage appeals. Medicare has also opened a pathway for Zepbound coverage when it's prescribed for OSA. Check your specific plan's criteria, since the landscape is shifting quickly.
Considering tirzepatide for weight management?
That's a separate question from the FDA sleep-apnea indication above. If your main goal is medically-supervised weight loss — where GLP-1 medications are most widely used — several telehealth platforms offer compounded tirzepatide programs (not FDA-approved, and not for sleep apnea, but a common lower-cost path under a provider's care).
Compounded medications are not FDA-approved and are not approved for sleep apnea. Affiliate links — we may earn a commission at no cost to you.
Common questions
Is compounded tirzepatide approved for sleep apnea?
No. Only brand-name Zepbound carries the FDA approval for moderate-to-severe OSA in adults with obesity. Compounded tirzepatide is not FDA-approved for any indication, including sleep apnea.
Can I stop using my CPAP if I start Zepbound?
Not on your own. Whether to change or stop PAP therapy is a decision for your sleep physician, ideally based on a follow-up sleep study. In the trials, many people improved, but that's a clinical decision, not a self-directed one.
Does Zepbound work directly on sleep?
No. It works through weight loss — reducing fat around the airway — rather than acting on the brain's sleep centers. That's why the approval is tied to people who have both OSA and obesity.
Do I need a sleep study first?
Generally yes — the indication is for moderate-to-severe OSA, which is diagnosed by a sleep study. A provider will determine what's needed in your case.